



Small Biotech Face to Face Breakfast Meeting

Tuesday, November 18th

7-8:30a.m.

Renaissance D.C. Downtown Hotel

Rm. 8-9

999 9th St. NW.

Washington, D.C.

Attendees

Joseph Araujo - InterVivo Solutions
Maria Carrillo – Alzheimer’s Association
Susan Catalano - Cognition Therapeutics
Kim Gannon - NeuroPhage Pharmaceuticals
Jim Hendrix – Alzheimer’s Association
Sam Kongsamut – Neurotrope Bioscience
John Levenson - NeuroPhage Pharmaceuticals
Richard Margolin - Cerespir
John Osth – NanoSomix
Charles Stacey - Inventages

Introduction and Meeting Purpose:

The meeting began with each attendee briefly introducing themselves and their company. Maria Carrillo welcomed the group and talked briefly about the Alzheimer’s Association and how important the biotech sector is to Alzheimer’s research. She expressed her hope that the group could come together to find areas of mutual benefit. Jim Hendrix also commented that while funding support is recognized as a major issue for small biotechs, the Alzheimer’s Association can’t solve these funding issues. Instead, the purpose of the group is to look for other areas of common interest that the group can work on together in a pre-competitive space to advance both the field of Alzheimer’s research and the member company’s goals. It was also pointed out that attendance at this meeting is not a commitment to join the group. The purpose of the meeting is just exploring possible consortia.

Open Forum:

The group brain stormed around items of possible focus for the group. Below are discussed items organized by topic.



1. Business Issues:

- a. For example, the US Jobs Act now makes it easier for small businesses to go public.
- b. Funding strategies and sources
 - i. SBIR Grants
 - ii. VC Funding
 - iii. Other funding agencies

2. Collaborations:

- a. Small companies with larger companies
- b. Collaborations within small companies
- c. Infrastructure issues and shared resources among small companies.
 - i. Example: Susan Catalano offered Cognition Therapeutics resources to members of the group.

3. Recognition & Visibility:

- a. Look for public relations and publication opportunities for the group.
- b. Draft a review article on biotech's in AD

4. Knowledge and Information Sharing:

- a. Group projects and sharing science
 - i. Example: The GBSC (Global Biomarker Standardization Consortia) convened by the Alzheimer's Association
 - ii. Case Studies
- b. An expert network including trusted consultants and CRO's
 - i. Example: NIH Blueprint
- c. An On-Line Forum for the group
- d. Data management in small companies

Meeting Close:

At the end of the meeting the group agreed to meet again via teleconference likely early in 2015 to further the discussion and focus next steps for advancing the team. In addition, it may be possible to organize another face-to-face meeting around the Alzheimer's Association International Conference in Washington D.C. in July of 2015.